Abdullah Bousamri

Dr. Abdullah Bousamri

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2026 in Cureus
Verified
Journal Article
Open access
PDF file
ABAbdullah Bousamri
Abdullah Bousamri
MAMohammad Al-Shehri
Mohammad Al-Shehri
MKMohammad Kana'An
Mohammad Kana'An
TATalal Almutairi
Talal Almutairi
FAFaisal Alharbi
Faisal Alharbi
AAAhmad Aburezq
Ahmad Aburezq
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that involves metabolic, hormonal, and inflammatory changes. These changes can affect tissues with high metabolic needs and sensitive microvascular systems. Optical coherence tomography (OCT) and OCT angiography (OCTA) are non-invasive ways to assess the structure and blood vessels of the retina and choroid. However, studies on women with PCOS have shown mixed results. This systematic review and meta-analysis set out to combine and analyze the available evidence on how PCOS affects retinal structure and microvasculature. We searched PubMed, Embase, Scopus, Web of Science, Cochrane CENTRAL, and Google Scholar from inception to February 1, 2026, for observational studies comparing OCT and OCTA results in women with PCOS and healthy controls. The main outcomes were average peripapillary retinal nerve fiber layer (RNFL) thickness, central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and vessel density in the superficial and deep capillary plexus (SCP, DCP). We used the Newcastle-Ottawa Scale (NOS) to check study quality and the GRADE framework to rate the certainty of the evidence. We performed random-effects meta-analyses using mean differences (MDs) and 95% confidence intervals (CIs). We included 15 observational studies with a total of 1,370 women (737 with PCOS and 633 controls), and 13 studies were used in the quantitative analysis. Women with PCOS had a higher average RNFL thickness (MD +3.75 µm; 95% CI 2.48 to 5.01; moderate-certainty evidence) and a small but significant decrease in CMT (MD −3.29 µm; 95% CI −6.46 to −0.11; moderate certainty) compared to controls. SFCT was also higher overall (MD +58.03 µm), but there was a lot of variation between studies (I² = 99%). Subgroup analysis showed that SFCT thickening was only seen in studies where disease duration was not specified, while studies with newly diagnosed PCOS patients found no significant difference. There were no significant differences in SCP or DCP vessel density (low-certainty evidence). PCOS is linked to consistent changes in the retina and choroid, including thicker RNFL and thinner central macula, while the density of retinal blood vessels seems unchanged. Choroidal thickening was only found in groups where the length of disease was not specified, whereas the newly diagnosed showed no change. This shows that future studies should track disease duration over time to better understand these changes.

Verified
Journal Article
Open access
PDF file
ABAbdullah Bousamri
Abdullah Bousamri
MKMohammad Qasim Kana'an
Mohammad Qasim Kana'an
FAFaisal Alharbi
Faisal Alharbi
NANoor M. Alqudah
Noor M. Alqudah
Background: Neovascular age-related macular degeneration (nAMD) remains a leading cause of irreversible central vision loss. Although anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed management, pivotal trials enrolled exclusively treatment-naïve patients, leaving clinicians without pooled evidence to guide switching decisions in previously treated eyes. This systematic review and meta-analysis assessed real-world visual, anatomical, durability, and safety outcomes following switching to aflibercept 8 mg in previously treated nAMD. Methods: Following PRISMA 2020 guidelines, we searched PubMed, Embase, Web of Science, CENTRAL, Scopus, and Google Scholar through April 2026. Studies reporting switching to aflibercept 8 mg with change in best-corrected visual acuity (BCVA), central subfield thickness (CST), or treatment interval were included. Continuous outcomes were pooled using random-effects models with Hartung–Knapp–Sidik–Jonkman adjustment; proportions were estimated using generalized linear mixed models. Methodological quality was evaluated using the JBI Critical Appraisal Checklist for Case Series. Certainty of evidence was assessed using GRADE. The protocol was registered with PROSPERO (CRD420261371334). Results: Twenty-one studies met inclusion criteria. BCVA remained stable (WMD: −0.017 logMAR; 95% CI: −0.027 to −0.007; +0.83 ETDRS letters; I2 = 0%). CST decreased significantly (WMD: −21.5 µm; 95% CI: −29.3 to −13.7; I2 = 56.0%), and treatment intervals extended by +1.79 weeks (95% CI: +1.32 to +2.27; I2 = 74.3%). Intraretinal and subretinal fluid each resolved in 37.5% of eyes. Intraocular inflammation was rare across 9959 treated eyes, though this pool was not restricted to switched eyes, with no confirmed retinal vasculitis. Sensitivity analyses confirmed robustness across all co-primary estimates. GRADE certainty was low for BCVA and very low for CST and treatment interval. Conclusions: Low-certainty evidence suggests that switching to aflibercept 8 mg preserves visual acuity, while very-low-certainty evidence suggests reductions in central subfield thickness and modest extension of treatment intervals. Intraocular inflammation was rare, though safety denominators included non-switch eyes. These findings provide preliminary pooled estimates to inform switch decisions in previously treated eyes.


1 October 2026 in Annals of Middle Eastern Medicine
Verified
Journal Article
Closed access
AAAya Abdulrahman Ajeel
Aya Abdulrahman Ajeel
AAAbdullah I. Alzimam
Abdullah I. Alzimam
SASharifah Alraythi
Sharifah Alraythi
AAAhmad Mohammad Mahmoud Altatari
Ahmad Mohammad Mahmoud Altatari
ABAbdullah Bousamri
Abdullah Bousamri
MAMansuor A. Alanazi
Mansuor A. Alanazi
Introduction: Chronic kidney disease (CKD) attributable to high fasting plasma glucose (HFPG) is rising globally, particularly in regions with rapidly increasing dysglycemia such as the Middle East and North Africa (MENA). We assessed long-term trends in HFPG-attributable CKD burden across 21 MENA countries from 1990 to 2023. Methods: Using estimates from the Global Burden of Disease (GBD) 2023 study, we quantified deaths and disability-adjusted life years (DALYs) attributable to HFPG-related CKD at regional, national, age-group, and sex-specific levels. We derived age-standardized mortality rates (ASMRs) and age-standardized DALY rates (ASDRs) and evaluated temporal changes using joinpoint regression to identify significant shifts in burden across the study period. Results: The absolute burden of HFPG-attributable CKD increased substantially across the region, with large rises in both deaths and DALYs. In contrast, ASMRs and ASDRs showed only modest changes, suggesting that population growth and ageing were major contributors to the rising burden. Older adults experienced the highest mortality and DALY rates, and men consistently exhibited greater burden at working ages. National patterns were heterogeneous, with some countries showing declining age-standardized rates while others demonstrated sustained increases. Joinpoint analysis revealed a transition from relative stability in the early 1990s to sustained increases after the late 2000s, with the most rapid acceleration occurring after 2019. Conclusion: HFPG-attributable CKD is an escalating health challenge in the MENA region, driven by rising dysglycemia and demographic change, with substantial variation across countries. Strengthening early detection of dysglycemia and CKD, improving long-term glycemic and blood-pressure control, and expanding access to kidney-protective therapies are critical to mitigating the growing burden.

10 April 2026 in Cureus
Verified
Journal Article
Open access
PDF file
ABAbdullah Bousamri
Abdullah Bousamri
MAMohammad Al-Shehri
Mohammad Al-Shehri
MMMohammad Mestarihi
Mohammad Mestarihi
TATalal B. Almutairi
Talal B. Almutairi
MAMateb Alaredhi
Mateb Alaredhi
BSBader Mahanna Sr.
Bader Mahanna Sr.
Polypoidal choroidal vasculopathy (PCV) is a distinct subtype of neovascular macular disease with variable responses to anti-vascular endothelial growth factor (anti-VEGF) therapy. This systematic review and meta-analysis evaluated the visual, anatomical, and lesion-regression outcomes of intravitreal aflibercept 8 mg, a formulation developed to extend dosing intervals while maintaining efficacy, in patients with PCV. PubMed, Embase, Scopus, Web of Science, and Google Scholar were searched from inception to March 12, 2026 (PROSPERO: CRD420261339679). Eligible studies enrolled adults with indocyanine green angiography (ICGA)-confirmed PCV treated with aflibercept 8 mg and reported at least one co-primary outcome: change in best-corrected visual acuity (BCVA), central retinal or subfield thickness (CRT/CST), or complete polyp regression. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2), Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I), and Joanna Briggs Institute (JBI) appraisal tools. Complete polyp regression was analyzed using a generalized linear mixed model with a logit link; continuous outcomes were pooled using restricted maximum likelihood estimation with the Hartung-Knapp-Sidik-Jonkman correction. Certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Five studies encompassing 362 eyes (245 treated with aflibercept 8 mg) were included. The pooled complete polyp regression rate was 57% (95% confidence interval (CI), 39%-73%; I2=55.9%; k=3). The pooled mean CRT/CST change was -157.8 µm (95% CI, -176.9 to -138.7 µm; I2=0%; k=2), though the estimate was predominantly driven by a single study contributing 95.5% of the inverse-variance weight. BCVA outcomes were not pooled due to metric incompatibility and clinical heterogeneity; however, individual study results were directionally favorable, with Early Treatment Diabetic Retinopathy Study (ETDRS) gains of +8.4 to +9.5 letters at 48 weeks in the largest contributing study. Extended dosing intervals were maintained in 80.5% (q12) and 86.5% (q16) of treated eyes at 48 weeks. One study reported intraocular inflammation in 10.8% of the overall neovascular age-related macular degeneration (AMD) cohort in that study, a safety signal not observed in the remaining studies. The certainty of evidence was low for CRT/CST change and very low for polyp regression and BCVA. Available evidence suggests that aflibercept 8 mg may produce clinically relevant polyp regression and substantial anatomical improvement in PCV, with a potential reduction in injection frequency. However, given the low to very low certainty of the current evidence base across all co-primary outcomes, definitive efficacy and safety conclusions cannot yet be drawn. Prospective, PCV-specific trials with standardized outcome reporting are needed.